Platelet Parameters—Consolidation
. | Group A . | Group B . | Placebo . |
---|---|---|---|
No. of patients | 31 | 15 | 23 |
Median peak platelet count (×109/L) | 416 | 498 | 409 |
Range | 73-2,425 | 49-1,041 | 66-1,101 |
Median time to peak platelet count after last dose (days) | 11 | 21 | 14 |
Range | 7-28 | 12-42 | 7-32 |
Median time to peak platelet count after start of chemotherapy (days) | 29 | 28 | 29 |
Range | 9-43 | 23-40 | 22-43 |
Percentage of patients with platelet count >1,000 × 109/L | 19% | 6% | 4% |
Median days to transfusion-independent platelet recovery >20 × 109/L | 17 | 19 | 19 |
Range | 14-48 | 15-34 | 15-42 |
. | Group A . | Group B . | Placebo . |
---|---|---|---|
No. of patients | 31 | 15 | 23 |
Median peak platelet count (×109/L) | 416 | 498 | 409 |
Range | 73-2,425 | 49-1,041 | 66-1,101 |
Median time to peak platelet count after last dose (days) | 11 | 21 | 14 |
Range | 7-28 | 12-42 | 7-32 |
Median time to peak platelet count after start of chemotherapy (days) | 29 | 28 | 29 |
Range | 9-43 | 23-40 | 22-43 |
Percentage of patients with platelet count >1,000 × 109/L | 19% | 6% | 4% |
Median days to transfusion-independent platelet recovery >20 × 109/L | 17 | 19 | 19 |
Range | 14-48 | 15-34 | 15-42 |